|52 Week Rng||-|
|P/E Ratio (TTM)||-|
|P/E Ratio (Fwd)||-|
|Div & Yield||-|
The company recently had its Malaria vaccine get recommended for use from the World Health Organization. This is the first vaccine on the market for this disease, so GSK effectively has a monopoly on this market. GSK has pledged to produce at least 15 million doses through 2028, so they will have sales volume for the foreseeable future as well.
Passive investment strategy | The Global 100 -list of sustainable stocks | Chosen 30 stocks from 9 individually weighted sectors, equal weights within sectors | Stocks available in NYSE or NASDAQ | Part of the Healthcare sector | The Global 100 rank 79 in year 2020